Spruce Street Capital LP Takes $16.70 Million Position in Enliven Therapeutics, Inc. $ELVN

Posted by Brenda Bartman on Aug 25th, 2026

Spruce Street Capital LP acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 329,006 shares of the company’s stock, valued at approximately $16,697,055. Enliven Therapeutics comprises approximately 0.0% of Spruce Street Capital LP’s investment portfolio, making the stock its 10th largest position. Spruce Street Capital LP owned approximately 0.45% of Enliven Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in ELVN. KBC Group NV acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at $38,000. State of Wyoming purchased a new position in Enliven Therapeutics during the 2nd quarter valued at about $96,000. FNY Investment Advisers LLC bought a new stake in shares of Enliven Therapeutics in the second quarter valued at about $126,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares during the period. 95.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $58.58, for a total value of $352,534.44. Following the completion of the transaction, the chief financial officer owned 40,036 shares of the company’s stock, valued at $2,345,308.88. This represents a 13.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the sale, the director owned 41,884 shares of the company’s stock, valued at approximately $2,114,723.16. This represents a 19.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 196,849 shares of company stock worth $11,344,257 over the last 90 days. 3.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ELVN shares. Mizuho raised their price target on Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a research report on Tuesday, August 18th. HC Wainwright lifted their target price on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Wall Street Zen downgraded shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Stifel Nicolaus boosted their price objective on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Barclays started coverage on Enliven Therapeutics in a report on Tuesday, August 18th. They set an “overweight” rating and a $78.00 target price for the company. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $75.00.

Read Our Latest Report on ELVN

Enliven Therapeutics Trading Down 3.7%

Shares of Enliven Therapeutics stock traded down $2.21 on Friday, hitting $58.29. 304,820 shares of the company traded hands, compared to its average volume of 1,237,525. Enliven Therapeutics, Inc. has a 52 week low of $14.78 and a 52 week high of $62.32. The company has a market cap of $4.27 billion, a PE ratio of -34.90 and a beta of 0.27. The stock’s 50 day moving average price is $54.36 and its 200-day moving average price is $42.99.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.69 EPS for the current fiscal year.

About Enliven Therapeutics

(Free Report)

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.